FSRH Guideline (February 2021) Progestogen-only Implant-Reference-Cited by-同舟云学术

FSRH Guideline (February 2021) Progestogen-only Implant

Published:2021-02 Issue:Suppl 1 Volume:47 Page:1-62
ISSN:2515-1991
Container-title:BMJ Sexual & Reproductive Health
language:en
Short-container-title:BMJ Sex Reprod Health

Author:

Publisher

BMJ

Subject

Obstetrics and Gynaecology,Reproductive Medicine

Reference219 articles.

1. Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study.;Schnabel;Clin Drug Investig,2012

2. Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial.;Mommers;Am J Obstet Gynecol,2012

3. Clinical trial with 3-keto-desogestrel subdermal implants

4. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel

5. electronic Medicines Compendium (eMC). Merck Sharp & Dohme Limited. Summary of Product Characteristics: Nexplanon 68 mg implant for subdermal use. Last updated on emc 16 January 2020. http://www.medicines.org.uk/emc/medicine/23824

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A nurse‐led model of care to improve access to contraception and abortion in rural general practice: Co‐design with consumers and providers;Journal of Advanced Nursing;2024-07-02

2. How COVID-19 continues to affect contraception in Scotland: a retrospective analysis of Scottish prescribing data between 2016 and 2023;2023-09-14

3. New FSRH guideline on the progestogen-only implant;BMJ Sexual & Reproductive Health;2021-04